drugset / Trial / NCT03390231

Stem Cell Educator Therapy in Diabetes

NCT03390231 ↗

NaSingle-groupOpen-labelTreatment

Summary

Stem Cell Educator (SCE) therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent Cord Blood Stem Cells (CB-SCs) in vitro, and returns only the "educated" autologous immune cells to the patient's circulation. Several mechanistic studies with clinical samples and animal models have demonstrated the proof of concept and clinical safety of SCE therapy. They suggest SCE therapy may function via CB-SC induction of immune tolerance in the autoimmune T cells and pathogenic monocytes/macrophages when these are exposed to the autoimmune regulator protein (AIRE) in the CB-SCs. In this project, the optimized SCE therapy for type 1 diabetes (T1D) and T2D will be tested in a prospective, single-arm, open-label, single-center study to assess its clinical efficacy and related molecular mechanisms in patients with diabetes.

Timeline

Start
2017-11-27
Primary completion
2020-12-30
Completion
2020-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Stem Cell Educator therapy Cell therapy — —